Guiding Vaccine Efficacy Trial Design During Public Health Emergencies: An interactive web-based decision support tool

The design and execution of rigorous, fast, and ethical vaccine efficacy trials can be challenging during epidemics of emerging pathogens, such as the 2014-2016 Ebola virus and 2015-2016 Zika virus epidemics. Response to an urgent public health crisis requires accelerated research even as emerging epidemics themselves change rapidly and are inherently less well understood than well-established diseases. As part of the World Health Organization Research and Development Blueprint, we designed a web-based interactive decision support system (InterVax-Tool) to help diverse stakeholders navigate the epidemiological, logistical, and ethical decisions involved in designing a vaccine efficacy trial during a public health emergency. In contrast to existing literature on trial design, InterVax-Tool offers high-level visual and interactive assistance through a set of four decision trees, guiding users through selection of 1) the Primary Endpoint, (2) the Target Population, (3) Randomization, and (4) the Comparator. Guidance is provided on how each of fourteen key considerations–grouped as Epidemiological, Vaccine-related, Infrastructural, or Sociocultural–should be used to inform each decision in the trial design process. The tool is not intended to provide a black box decision framework for identifying an optimal trial design, but rather to facilitate transparent, collaborative and comprehensive discussion of the relevant decisions, while recording the decision process. The tool can also assist capacity building by providing a cross-disciplinary picture of trial design using concepts from epidemiology, study design, vaccinology, biostatistics, mathematical modeling and clinical research ethics. Here, we describe the goals and features of InterVax-Tool as well as its application to the design of a Zika vaccine efficacy trial. One Sentence Summary An interactive web-based decision support tool was developed to assist in the design of vaccine efficacy trials during emerging outbreaks.

[1]  Marc Lipsitch,et al.  Vaccine testing for emerging infections: the case for individual randomisation , 2017, Journal of Medical Ethics.

[2]  Emily R. Busta,et al.  Integrating Clinical Research into Epidemic Response: The Ebola Experience , 2017 .

[3]  Annette Rid,et al.  Ethical Rationale for the Ebola "Ring Vaccination" Trial Design. , 2016, American journal of public health.

[4]  Edward C Holmes,et al.  Predicting virus emergence amid evolutionary noise , 2017, Open Biology.

[5]  Stephen Morrissey,et al.  We Can Do Better - Improving Outcomes in the Midst of an Emergency. , 2017, The New England journal of medicine.

[6]  Claudio J. Struchiner,et al.  Design and Analysis of Vaccine Studies , 2009 .

[7]  Vandebosch,et al.  Real-time dynamic modelling for the design of a cluster- , .

[8]  Kent Buse,et al.  Recognition matters: only one in ten awards given to women , 2017, The Lancet.

[9]  Marie Paule Kieny,et al.  WHO R&D Blueprint: a global coordination mechanism for R&D preparedness , 2017, The Lancet.

[10]  Lauren Ancel Meyers,et al.  Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis. , 2015, The Lancet. Infectious diseases.

[11]  David S. Ebert,et al.  Visual analytics decision support environment for epidemic modeling and response evaluation , 2011, 2011 IEEE Conference on Visual Analytics Science and Technology (VAST).

[13]  Christl A. Donnelly,et al.  Considerations for the design of vaccine efficacy trials during public health emergencies , 2018, bioRxiv.

[14]  Kathryn H. Bowles,et al.  Implementation and Testing of Interdisciplinary Decision Support Tools to Standardize Discharge Planning , 2012, Nursing Informatics.

[15]  Daniela Fogli,et al.  Knowledge-centered design of decision support systems for emergency management , 2013, Decis. Support Syst..

[16]  Lauren Ancel Meyers,et al.  Quantifying ethical tradeoffs for vaccine efficacy trials during severe epidemics , 2017, bioRxiv.

[17]  John-Arne Røttingen,et al.  The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola , 2015, BMJ : British Medical Journal.

[18]  Sebastian Funk,et al.  Estimating the probability of demonstrating vaccine efficacy in the declining Ebola epidemic: a Bayesian modelling approach , 2015, BMJ Open.

[19]  Alessandro Vespignani,et al.  Simulations for designing and interpreting intervention trials in infectious diseases , 2017, bioRxiv.

[20]  Anthony Dudo,et al.  The “Science” of Science Communication , 2013 .

[21]  Detlof von Winterfeldt,et al.  Bridging the gap between science and decision making , 2013, Proceedings of the National Academy of Sciences.

[22]  S. Funk,et al.  Real-time dynamic modelling for the design of a cluster-randomized phase 3 Ebola vaccine trial in Sierra Leone. , 2017, Vaccine.